Liquid-like layer coated intraocular lens for posterior capsular opacification prevention

Wu, Qianni; Liu, Dong; Chen, Wan; Chen, Hui; Yang, Cheng; Li, Xiangling; Yang, Chengduan; Lin, Haotian; Chen, Shuyi; Hu, Ning; Chen, Weirong; Xie, Xi

doi:10.1016/j.apmt.2021.100981

Cited by 10 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCO mainly comes from the proliferation, migration, fibrosis, and EMT of LECs in the lens capsule after stimulation by several growth factors and cytokines [ 43 ]. The development of anterior subcapsular cataract (ASC) and PCO closely relates to the EMT of LECs triggered by a diverse set of stimuli, of which the TGF-β2 growth factor is one of the most [ 44 , 45 ].…”

Section: Discussionmentioning

confidence: 99%

Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification

Zhang

Lai

et al. 2022

Bioactive Materials

View full text Add to dashboard Cite

Cataract is the leading cause of visual impairment, and posterior capsular opacification (PCO) is the most common long-term complication of modern cataract surgery, which can cause severe visual impairment after surgery. The proliferation, migration, and epithelial-mesenchymal transition (EMT) of residual lens epithelial cells (LECs) stimulated by growth factors and cytokines, are the key pathological mechanisms involved in the development of PCO. This study demonstrated that non-steroidal anti-inflammatory drug (NSAID), bromfenac, was capable of effectively inhibiting cell migration, overexpression of EMT markers, such as fibronectin (FN), matrix metalloproteinase 2 (MMP2), α-smooth muscle actin (α-SMA), and transcription factor Snail, and extracellular signal-regulated kinase (ERK)/glycogen synthase kinase-3β (GSK-3β) signaling induced by transforming growth factor-β2 (TGF-β2) in vitro . The inhibitory effect of bromfenac on TGF-β2-induced EMT was also verified on a primary lens epithelial cell model using human anterior capsules. Furthermore, based on ultrasonic spray technology, we developed a drug-eluting intraocular lens (IOL) using poly (lactic-co-glycolic acid) (PLGA) with sustained bromfenac release ability for the prevention of PCO development. In the rabbit models of cataract surgery, bromfenac-eluting IOL exhibited remarkable PCO prevention and inflammation suppression effects with excellent biocompatibility. In conclusion, bromfenac can inhibit TGF-β2-induced cell migration and the EMT of LECs via ERK/GSK-3β/Snail signaling. The present study offers a novel approach for preventing PCO through PLGA-based drug sustained-release IOLs.

show abstract

Section: Discussionmentioning

confidence: 99%

Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification

Zhang

Lai

et al. 2022

Bioactive Materials

View full text Add to dashboard Cite

show abstract

“…In order to prevent posterior capsular opacification after intraocular lens implantation, the intraocular lens made of acrylic resin are treated. 99 The surface of acrylic resin was treated in oxygen plasma to form a nanoscale rough structure, as shown in Fig. 8(A).…”

Section: Controlling Pathological Crystallization By Means Of Materia...mentioning

confidence: 99%

Progress in the regulation of pathological crystallization

Li,

Meng,

et al. 2023

CrystEngComm

View full text Add to dashboard Cite

show abstract

“…The modified IOLs mentioned above were rarely resistant to biofouling while maintaining tight contact with the posterior capsule. Thus, Wu et al [ 43 ] fabricated a new type of IOL with a hydrophobic anti-biofouling coating ( Figure 3 ). After functionalizing the nanomorphology of the hydrophobic IOL surface and covalently conjugating it with a “liquid-like” polydimethylsiloxane brush, the resulting (NT + LLL)-IOL exhibited strong resistance to biological fouling, including proteins, cells, and bacteria, because of the low surface energy of the modified surface.…”

Section: The Main Types Of Iols Used For Pco Prophylaxismentioning

confidence: 99%

Research Progress Concerning a Novel Intraocular Lens for the Prevention of Posterior Capsular Opacification

Zhang

Zhang²,

Chen³

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Posterior capsular opacification (PCO) is the most common complication resulting from cataract surgery and limits the long-term postoperative visual outcome. Using Nd:YAG laser-assisted posterior capsulotomy for the clinical treatment of symptomatic PCO increases the risks of complications, such as glaucoma, retinal diseases, uveitis, and intraocular lens (IOL) pitting. Therefore, finding how to prevent PCO development is the subject of active investigations. As a replacement organ, the IOL is implanted into the lens capsule after cataract surgery, but it is also associated with the occurrence of PCO. Using IOL as a medium for PCO prophylaxis is a more facile and efficient method that has demonstrated various clinical application prospects. Thus, scientists have conducted a lot of research on new intraocular lens fabrication methods, such as optimizing IOL materials and design, and IOL surface modification (including plasma/ultraviolet/ozone treatment, chemical grafting, drug loading, coating modification, and layer-by-layer self-assembly methods). This paper summarizes the research progress for different types of intraocular lenses prepared by different surface modifications, including anti-biofouling IOLs, enhanced-adhesion IOLs, micro-patterned IOLs, photothermal IOLs, photodynamic IOLs, and drug-loading IOLs. These modified intraocular lenses inhibit PCO development by reducing the residual intraoperative lens epithelial cells or by regulating the cellular behavior of lens epithelial cells. In the future, more works are needed to improve the biosecurity and therapeutic efficacy of these modified IOLs.

show abstract

Liquid-like layer coated intraocular lens for posterior capsular opacification prevention

Cited by 10 publications

References 38 publications

Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification

Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification

Progress in the regulation of pathological crystallization

Research Progress Concerning a Novel Intraocular Lens for the Prevention of Posterior Capsular Opacification

Contact Info

Product

Resources

About